Marc S. Raab

Clinician and scientist focusing on multiple myeloma. Chair, GMMG study group. Tweets are my own. @HDMyeloma @ukhd @dkfz

[Marc S. Raab @RaabMarc]

@DrGarethMorgan1 @RahulBanerjeeMD iMMpressive!!

[VJHemOnc @VJHemOnc]

@RaabMarc of @HDMyeloma is kicking off day 2 of #iwHRMM26 with his talk on 'T-cell engager combinations to overcome HR #MultipleMyeloma'.

#MMsm #ImmunoOnc #Myeloma

[Gareth Morgan @DrGarethMorgan1]

Spirited debate about how to treat high-risk myeloma at the iwHRMM

[VJHemOnc @VJHemOnc]

#iwHRMM26 | @FaithEDavies1 of @nyulangone is currently on stage presenting on 'Defining a high-risk microenvironment'.

#MultipleMyeloma #MMsm #Myeloma #HemOnc

[Marc S. Raab @RaabMarc]

@HenrychihangFu1 Agree 💯 and that’s exactly what my bottom line conclusion was 🙂

[Myeloma Society @Myeloma_Society]

Marc Raab, MD, discussed cure in the context of the GEM14MAIN & MajesTEC-5 data shared during #IMS26. He also summarized studies on improving CAR-T safety and monitoring/managing bone disease during the Highlights session. @RaabMarc

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#IMS26 Tal-DR in newly diagnosed ASCT-eligible myeloma. More excellent MajesTEC-5 by @RascheLeo @RaabMarc et al! 👏

No issues with SC collection. Excellent response 👇🏼. 15% ataxia (all low-grade & recovering) - perhaps combo Tx, or truly more common as tal enters earlier lines?

[Heidelberg Myeloma @HDMyeloma]

This weekend, we bid farewell to Hartmut Goldschmidt, who will retire from his academic positions at the end of the month. To celebrate 35 years of @HDMyeloma, 30 years of #GMMG, a large crowd joined us for a dedicated symposium with long-standing partners and friends. #mmsm

[Marc S. Raab @RaabMarc]

@VincentRK @JanakiramMurali @IMFmyeloma @MayoClinic Very sorry to hear !! A true legend and one of the most impressive teachers I ever had the honor to learn from

[Marc S. Raab @RaabMarc]

Lively discussion on functional high risk myeloma at the IMS Genomics Workshop 2026 in Warsaw, Poland
#mmsm
@MyMKaiser @BrunoPaiva_UNAV @szusmani @NBahlis @nickbolli @FrancescoMaura4 @IrenemGhobrial

[Myeloma Society @Myeloma_Society]

Mark your calendars for the 4th Annual Workshop on Genomics. 📅 July 10-11 in Warsaw, Poland. Register today for in-person or virtual attendance! https://t.co/Y3I03jsEqJ

[Saurabh Zanwar @ZanwarSaurabh]

GMMG-HD10/MajesTEC-5 represents an important and likely a watershed moment in myeloma induction and consolidation therapy! Amazing early and deep responses (100% MRD neg rates!!)
👏👏 @RascheLeo @RaabMarc et al.

AntiCD38-based quadruplets set the bar pretty high for early PFS rates PFS and now we have a worthy challenger!

Whether this eventually displaces autologous transplant or not, one thing is for sure—BCMA bispecifics in induction will certainly make all of us think like transplanters when it comes to our infectious disease game (>35% Gr3 infections, 6% CMV reactivation).

Biggest question that will need answering is whether everyone need a BCMA TCE upfront and for how long?

https://t.co/kr380rUtuk

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Love seeing triple-digit MRD neg percentages 🤩

Congrats @RaabMarc et al on excellent MajesTEC-5 @NatureMedicine paper!

bsAb-based induction in ND myeloma - may well obviate ASCT.

Top panel = ITT, bottom = MRD-evaluable. Kudos to authors for reporting both sets like this.

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Teclistamab-based induction in TE NDMM shows MRD- CR rate 91.8% (45/49) by pre-maintenance timepoint, 100% in evaluable samples & post-induction cycle 3 (10-5 (46/46)), 6 (10-5 (46/46) & 10-6 (46/46)); ORR was 100%: https://t.co/JI0HRixT9o. #mmsm

[nizar jacques bahlis @NBahlis]

Anti-BCMA TCE in newly diagnosed myeloma. New era is here, end of HCT? congrats @RaabMarc @RascheLeo https://t.co/qkK5AsaonW

[Mostafa Faisal @MostafaFaisal14]

Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
@BCD_AACR
https://t.co/BjSAYEVbUg

[Marc S. Raab @RaabMarc]

@RahulBanerjeeMD @Drjhoffmanmiami @Someone68423357 Agree, we need data for both scenarios

[Marc S. Raab @RaabMarc]

@NBahlis @MyMKaiser Prague @EMN_EuMMnet

[Marc S. Raab @RaabMarc]

Work and life need to be balanced
@MyMKaiser #EMN2026

[Blood Cancer Discovery @BCD_AACR]

Now online: Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy https://t.co/JvdypWnpvG

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Fascinating - albeit a little terrifying - @LeukemiaJnl work by 🇩🇪

How does GPRC5D loss affect surviving myeloma #MMsm clones? Here, remaining cells appear to be more aggressive.

Will be important to validate / rebut as talquetamab moves into earlier lines... hopefully soon!